GET DAILY SIGNALSTonix Pharmaceuticals (TNXP) Shows TONMYA Momentum in Q3 2026 Despite Wider Losses
Key Takeaways
- Tonix Pharmaceuticals reported third quarter 2026 net product revenue of approximately $17.2 million, up from $3.3 million in the same period last year.
- Net sales of its lead commercial product, TONMYA, reached roughly $15 million, an increase of 37% from the second quarter of 2026.
- The company posted a net loss available to common stockholders of $53.3 million, or $2.89 per share, compared with a loss of $32.0 million, or $3.59 per share, a year earlier.
- Reported earnings per share (EPS) came in below analyst consensus estimates, while quarterly revenue modestly exceeded expectations.
- Cash and cash equivalents totaled approximately $163 million as of September 30, 2026, which management expects to fund operations into the early third quarter of 2027.
Earnings Context and Why It Matters
Tonix Pharmaceuticals is a biopharmaceutical company focused on commercializing and developing treatments for central nervous system disorders. Its third quarter 2026 results represent the first full-year cycle in which TONMYA, the fibromyalgia therapy launched in November 2025, is making a meaningful contribution to revenue. I am watching closely to see whether TONMYA prescription growth and payer coverage can scale rapidly enough to offset the substantial commercial and research investments supporting the launch. The quarter also highlighted balance sheet considerations, as the company manages commercialization costs against a cash position expected to last into the early third quarter of 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Tonix reported net product revenue of approximately $17.2 million for the third quarter ended September 30, 2026, compared with $3.3 million in the prior-year period. The result was driven by roughly $15.0 million in net sales of TONMYA, while sales of the migraine products Zembrace SymTouch and Tosymra contributed about $2.2 million, down from $3.3 million a year earlier.
Net loss available to common stockholders widened to $53.3 million, or $2.89 per basic and diluted share, versus $32.0 million, or $3.59 per share, in the third quarter of 2025. The reported EPS of negative $2.89 missed consensus estimates, while revenue slightly beat expectations. The wider loss reflected higher spending: research and development expenses rose to approximately $25.8 million from $9.3 million, and selling, general, and administrative expenses climbed to about $45.6 million from $25.7 million, largely tied to TONMYA commercialization efforts.
Tonix ended the quarter with approximately $163 million in cash and cash equivalents, down from $207.6 million at the end of 2025, and reported 19,431,516 shares of common stock outstanding as of November 6, 2026.
Market Reaction and Investor Sentiment
Investor sentiment around the third quarter results was mixed. TONMYA's 37% sequential sales growth and a 28% quarter-over-quarter rise in total prescriptions were clear positive signals, supported by expanded payer coverage reaching roughly 166 million U.S. lives and a larger sales force. However, the wider-than-expected net loss and the sharp increase in operating expenses weighed on sentiment, with the stock trading lower following the release. The market also appeared to focus on the narrowing cash runway and the need for potential future financing or partnerships, alongside the disclosure that Dr. Reddy's filed an abbreviated new drug application Paragraph IV patent certification for TONMYA, which TNXP intends to defend.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central question is whether TONMYA's commercial momentum can translate into sustained revenue growth that narrows the company's losses over time. Management has pointed to continued month-over-month prescription growth into 2027, aided by expanding payer coverage and improving gross-to-net trends. Investors should monitor prescription trends, refill rates, and any changes in net pricing as the commercial launch matures.
On the pipeline, three clinical programs carry near-term catalysts. The Phase 2 HORIZON study of TNX-102 SL for major depressive disorder continues enrollment, while the Phase 2 TRAIL study of TNX-4800 for Lyme disease prevention and an investigator-initiated Phase 2 study of TNX-1500 for kidney transplant rejection prevention are both expected to begin in the first quarter of 2027.
Cost control and cash management will remain key watchpoints. With R&D and SG&A spending rising sharply, investors will be looking for evidence that spending begins to moderate or that revenue growth accelerates. The outcome of the TONMYA patent litigation initiated by Dr. Reddy's will also be closely followed, given its potential implications for the product's market exclusivity.
Exploring AI Tools in My Research
In my analysis of biopharma names like TNXP, I often turn to Tickeron’s AI Screener to quickly filter sector peers by technical patterns, fundamentals, and performance metrics. It helps surface comparable opportunities efficiently without replacing deeper fundamental review. This approach keeps my screening process consistent and data-driven when evaluating launch-stage companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TNXP in -11.37% downward trend, falling for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TNXP declined for three days, in 355 of 376 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for TNXP entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TNXP just turned positive on October 27, 2026. Looking at past instances where TNXP's MACD turned positive, the stock continued to rise in 24 of 31 cases over the following month. The odds of a continued upward trend are 77%.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNXP advanced for three days, in 180 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
TNXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.498). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing and manufacturing pharmaceuticals
Industry Biotechnology
Advertisement